Previous 10 | Next 10 |
For 2022, I am going to focus on those companies poised to benefit from the tragic COVID-19 pandemic. I maintain that SARS-CoV-2 will be with us for a long time. As for the proposed drug price legislation in BBBA, it would impact biologics (high cost medications) only near the end of ...
Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting PR Newswire PALO ALTO, Calif. , Dec. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the dev...
The following slide deck was published by Eiger BioPharmaceuticals, Inc. in conjunction with this event. For further details see: Eiger Biopharmaceuticals (EIGR) AT HDV KOL Event - Slideshow
Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences PR Newswire PALO ALTO, Calif. , Nov. 10, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the dev...
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Sri Ryali – Chief Financial Officer David Cory – President and Chief Executive Officer Ingrid Choong – Senior Vice President-Clinical Development Eldon ...
Eiger BioPharmaceuticals (NASDAQ:EIGR): Q3 GAAP EPS of -$0.65 misses by $0.09. Revenue of $3.03M beats by $0.1M. Press Release For further details see: Eiger BioPharmaceuticals EPS misses by $0.09, beats on revenue
Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) Enrolled; Topline Data Planned by End of 2022 - Phase 3 HDV LIMT-2 (Peginterferon Lambda) Enrolling - Company to Host Conference Call Toda...
Eiger BioPharmaceuticals (NASDAQ:EIGR) is scheduled to announce Q3 earnings results on Thursday, November 4th, after market close. The consensus EPS Estimate is -$0.53 and the consensus Revenue Estimate is $2.93M Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downwar...
Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15 PR Newswire PALO ALTO, Calif. , Nov. 2, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biop...
Eiger BioPharmaceuticals (NASDAQ:EIGR) announces completion of enrollment in the Phase 3 D-LIVR study evaluating two different treatment regimens containing Lonafarnib for the treatment of chronic hepatitis delta virus (HDV) infection. The two regimens include all-oral Lonafarnib boosted...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...